Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Enhertu
Pharma
AZ, Daiichi's Enhertu helps patients with brain metastases
Daiichi Sankyo and AstraZeneca are padding the case for Enhertu with new data showing the ADC's worth in patients whose cancer has reached the brain.
Fraiser Kansteiner
Sep 13, 2024 11:04am
AZ, Daiichi's Enhertu turned away by NICE on pricing grounds
Jul 29, 2024 9:16am
China deals, Enhertu, Samsung Bio—Fierce Pharma Asia
Jul 26, 2024 1:45am
Enhertu stalls as AZ, Daiichi navigate 'harder yards' for ADC
Jul 25, 2024 11:12am
Daiichi Sankyo closes ADC patent arbitration with $47M win
Jun 28, 2024 10:36am
Daiichi, Akeso, Genscript and Legend— Fierce Pharma Asia
Jun 7, 2024 6:00am
